Report Company Directory

Biodel Inc

BioDelivery Sciences International Inc.

• BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine by GlobeNewsWire
• Collegium to Acquire BioDelivery Sciences in an All-Cash Deal by GlobeNewsWire
• BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance by GlobeNewsWire
• BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference by GlobeNewsWire
• BioDelivery Sciences Reports Second Quarter 2021 Results by GlobeNewsWire
• BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine by GlobeNewsWire
• BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021 by GlobeNewsWire
• BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021 by GlobeNewsWire
• BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results by GlobeNewsWire
• BIODELIVERY SCIENCES sees an upgrade to Slightly Positive due to a better fundamental star rating by TheScreener

Biodesix

• Biodesix to Present New Data at Two Major Upcoming Scientific Meetings by GlobeNewsWire
• Biodesix Announces Third Quarter 2025 Results and Highlights by GlobeNewsWire
• Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting by GlobeNewsWire
• Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays by GlobeNewsWire
• Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025 by GlobeNewsWire
• Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting by GlobeNewsWire
• Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit by GlobeNewsWire
• InsiderInsights.com Daily Ratings Report: September 23, 2025 by InsiderInsights.com
• Biodesix Announces One-for-Twenty Reverse Stock Split by GlobeNewsWire
• Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference by GlobeNewsWire

BIODESIX INC

• William Blair’s 2026 Top Picks Discussions: December 8–12, 2025 by William Blair
• William Blair’s 2026 Top Picks Discussions: December 8–12, 2025 by William Blair
• William Blair’s 2026 Top Picks Discussions: December 8–12, 2025 by William Blair
• Third-Quarter Earnings Wrap-up, Updated Top Ideas, Sector Macro Thoughts, and Thanksgiving Plans by William Blair
• William Blair’s 2026 Top Picks Discussions: December 8–12, 2025 by William Blair
• What’s Going on With the Respiratory Season? Government Shutdown Makes Tracking Difficult, but Not Impossible by William Blair
• Getting Back on Track With a Beat-and-Raise Quarter by William Blair
• Happy Halloween! Thoughts Ahead of Key Diagnostic Company Prints by William Blair
• Thoughts Ahead of Key Prints, Happenings in the Space, and Halloween Candy by William Blair
• The Week Ahead: Thoughts Into Key Prints for the Week of October 20 by William Blair

BIODEXA PHARMACEUTICALS PLC

• Biodexa Announces Pricing of $10 Million Public Offering by GlobeNewsWire
• Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP by GlobeNewsWire
• Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP by GlobeNewsWire
• Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion by GlobeNewsWire
• Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025 by GlobeNewsWire
• Interim results for the six months ended June 30, 2025 by GlobeNewsWire
• Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) by GlobeNewsWire
• ADR Ratio Change Effective by GlobeNewsWire
• ADR Ratio Change by GlobeNewsWire
• Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) by GlobeNewsWire